PrognoScan: A new database for meta-analysis of the prognostic value of genes

BMC Medical Genomics

Volumn 2, Issue , 2009, Pages

  Mizuno, Hideaki ^a,b   Kitada, Kunio ^a   Nakai, Kenta ^c   Sarai, Akinori ^b  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^b KYUSHU INSTITUTE OF TECHNOLOGY   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER PATIENT; CANCER RESEARCH; CANCER SURVIVAL; DATA ANALYSIS; DATA SYNTHESIS; DNA MICROARRAY; FACTUAL DATABASE; GENE EXPRESSION PROFILING; HUMAN; META ANALYSIS; MICROARRAY ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSCAN; PROGNOSIS;

EID: 67650670767     PISSN: None     EISSN: 17558794     Source Type: Journal    
DOI: 10.1186/1755-8794-2-18     Document Type: Article

References (61)

1. ITTACA: a new database for integrated tumor transcriptome array and clinical data analysis. A Elfilali S Lair C Verbeke P La Rosa F Radvanyi E Barillot, Nucleic Acids Res 2006 34 D613 6 16381943 10.1093/nar/gkj022
2. CRITLEVEL: an exploratory procedure for the evaluation of quantitative prognostic factors. U Abel J Berger H Wiebelt, Methods Inf Med 1984 23 154 6 6548543
3. Quantitative thresholds for mitotic counts in histologic grading: confirmation in nonfrozen samples of invasive ductal breast cancer. P Kronqvist T Kuopio Y Collan, Ann Diagn Pathol 2000 4 65 70 10.1016/S1092-9134(00)90013-3 10760318 (Pubitemid 30750906)
4. New cutpoints to identify increased HER2 copy number: analysis of a large, population-based cohort with long-term follow-up. KC Jensen DA Turbin S Leung MA Miller K Johnson B Norris T Hastie S McKinney TO Nielsen DG Huntsman CB Gilks RB West, Breast Cancer Res Treat 2008 112 453 9 10.1007/s10549-007-9887-y 18193353
5. Bub1 mediates cell death in response to chromosome missegregation and acts to suppress spontaneous tumorigenesis. K Jeganathan L Malureanu DJ Baker SC Abraham JM van Deursen, J Cell Biol 2007 179 255 67 17938250 10.1083/jcb.200706015
6. HOXB4 inhibits cell growth in a dose-dependent manner and sensitizes cells towards extrinsic cues. E Will D Speidel Z Wang G Ghiaur A Rimek B Schiedlmeier DA Williams C Baum W Ostertag H Klump, Cell Cycle 2006 5 14 22 16357528
7. Genomic and proteomic analysis reveals a threshold level of MYC required for tumor maintenance. CM Shachaf AJ Gentles S Elchuri D Sahoo Y Soen O Sharpe OD Perez M Chang D Mitchel WH Robinson D Dill GP Nolan SK Plevritis DW Felsher, Cancer Res 2008 68 5132 42 10.1158/0008-5472.CAN-07-6192 18593912
8. NCBI GEO: mining tens of millions of expression profiles database and tools update. T Barrett DB Troup SE Wilhite P Ledoux D Rudnev C Evangelista IF Kim A Soboleva M Tomashevsky R Edgar, Nucleic Acids Res 2007 35 D760 5 17099226 10.1093/nar/gkl887
9. ArrayExpress a public database of microarray experiments and gene expression profiles. H Parkinson M Kapushesky M Shojatalab N Abeygunawardena R Coulson A Farne E Holloway N Kolesnykov P Lilja M Lukk R Mani T Rayner A Sharma E William U Sarkans A Brazma, Nucleic Acids Res 2007 35 D747 50 17132828 10.1093/nar/gkl995
10. Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer. AB Als L Dyrskjøt H von der Maase K Koed F Mansilla HE Toldbod JL Jensen BP Ulhøi L Sengeløv KM Jensen TF Orntoft, Clin Cancer Res 2007 13 4407 14 10.1158/1078-0432.CCR-07-0109 17671123
11. An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. KH Metzeler M Hummel CD Bloomfield K Spiekermann J Braess MC Sauerland A Heinecke M Radmacher G Marcucci SP Whitman K Maharry P Paschka RA Larson WE Berdel T Büchner B Wörmann U Mansmann W Hiddemann SK Bohlander C Buske Cancer and Leukemia Group B; German AML Cooperative Group, Blood 2008 112 4193 201 10.1182/blood-2008-02-134411 18716133
12. A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia. M Raponi JE Lancet H Fan L Dossey G Lee I Gojo EJ Feldman J Gotlib LE Morris PL Greenberg JJ Wright JL Harousseau B Löwenberg RM Stone P De Porre Y Wang JE Karp, Blood 2008 111 2589 96 10.1182/blood-2007-09-112730 18160667
13. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. M Hummel S Bentink H Berger W Klapper S Wessendorf TF Barth HW Bernd SB Cogliatti J Dierlamm AC Feller ML Hansmann E Haralambieva L Harder D Hasenclever M Kühn D Lenze P Lichter JI Martin-Subero P Möller HK Müller-Hermelink G Ott RM Parwaresch C Pott A Rosenwald M Rosolowski C Schwaenen B Stürzenhofecker M Szczepanowski H Trautmann HH Wacker R Spang M Loeffler L Trümper H Stein R Siebert Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe, N Engl J Med 2006 354 2419 30 10.1056/NEJMoa055351 16760442
14. The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab. JP Jais C Haioun TJ Molina DS Rickman A de Reynies F Berger C Gisselbrecht J Brière F Reyes P Gaulard P Feugier E Labouyrie H Tilly C Bastard B Coiffier G Salles K Leroy Groupe d'Etude des Lymphomes de l'Adulte, Leukemia 2008 22 1917 24 18615101 10.1038/leu.2008.188
15. The molecular classification of multiple myeloma. F Zhan Y Huang S Colla JP Stewart I Hanamura S Gupta J Epstein S Yaccoby J Sawyer B Burington E Anaissie K Hollmig M Pineda-Roman G Tricot F van Rhee R Walker M Zangari J Crowley B Barlogie JD Shaughnessy Jr, Blood 2006 108 2020 8 16728703 10.1182/blood-2005-11-013458
16. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. K Chin S DeVries J Fridlyand PT Spellman R Roydasgupta WL Kuo A Lapuk RM Neve Z Qian T Ryder F Chen H Feiler T Tokuyasu C Kingsley S Dairkee Z Meng K Chew D Pinkel A Jain BM Ljung L Esserman DG Albertson FM Waldman JW Gray, Cancer Cell 2006 10 529 41 10.1016/j.ccr.2006.10.009 17157792
17. The humoral immune system has a key prognostic impact in node-negative breast cancer. M Schmidt D Böhm C von Törne E Steiner A Puhl H Pilch HA Lehr JG Hengstler H Kölbl M Gehrmann, Cancer Res 2008 68 5405 13 10.1158/0008-5472.CAN-07-5206 18593943
18. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. XJ Ma Z Wang PD Ryan SJ Isakoff A Barmettler A Fuller B Muir G Mohapatra R Salunga JT Tuggle Y Tran D Tran A Tassin P Amon W Wang W Wang E Enright K Stecker E Estepa-Sabal B Smith J Younger U Balis J Michaelson A Bhan K Habin TM Baer J Brugge DA Haber MG Erlander DC Sgroi, Cancer Cell 2004 5 607 16 10.1016/j.ccr.2004.05.015 15193263
19. Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Y Pawitan J Bjöhle L Amler AL Borg S Egyhazi P Hall X Han L Holmberg F Huang S Klaar ET Liu L Miller H Nordgren A Ploner K Sandelin PM Shaw J Smeds L Skoog S Wedrén J Bergh, Breast Cancer Res 2005 7 R953 64 16280042 10.1186/bcr1325
20. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Y Wang JG Klijn Y Zhang AM Sieuwerts MP Look F Yang D Talantov M Timmermans ME Meijer-van Gelder J Yu T Jatkoe EM Berns D Atkins JA Foekens, Lancet 2005 365 671 9 15721472
21. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. C Sotiriou P Wirapati S Loi A Harris S Fox J Smeds H Nordgren P Farmer V Praz B Haibe-Kains C Desmedt D Larsimont F Cardoso H Peterse D Nuyten M Buyse MJ Van de Vijver J Bergh M Piccart M Delorenzi, J Natl Cancer Inst 2006 98 262 72 16478745
22. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. AH Bild G Yao JT Chang Q Wang A Potti D Chasse MB Joshi D Harpole JM Lancaster A Berchuck JA Olson Jr JR Marks HK Dressman M West JR Nevins, Nature 2006 439 353 7 10.1038/nature04296 16273092
23. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. LD Miller J Smeds J George VB Vega L Vergara A Ploner Y Pawitan P Hall S Klaar ET Liu J Bergh, Proc Natl Acad Sci USA 2005 102 13550 5 16141321 10.1073/pnas.0506230102
24. Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. AV Ivshina J George O Senko B Mow TC Putti J Smeds T Lindahl Y Pawitan P Hall H Nordgren JE Wong ET Liu J Bergh VA Kuznetsov LD Miller, Cancer Res 2006 66 10292 301 10.1158/0008-5472.CAN-05-4414 17079448
25. Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. S Loi B Haibe-Kains C Desmedt P Wirapati F Lallemand AM Tutt C Gillet P Ellis K Ryder JF Reid MG Daidone MA Pierotti EM Berns MP Jansen JA Foekens M Delorenzi G Bontempi MJ Piccart C Sotiriou, BMC Genomics 2008 9 239 18498629 10.1186/1471-2164-9-239
26. Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer. Y Zhou C Yau JW Gray K Chew SH Dairkee DH Moore U Eppenberger S Eppenberger-Castori CC Benz, BMC Cancer 2007 7 59 17407600 10.1186/1471-2407-7-59
27. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. C Desmedt F Piette S Loi Y Wang F Lallemand B Haibe-Kains G Viale M Delorenzi Y Zhang MS d'Assignies J Bergh R Lidereau P Ellis AL Harris JG Klijn JA Foekens F Cardoso MJ Piccart M Buyse C Sotiriou TRANSBIG Consortium, Clin Cancer Res 2007 13 3207 14 10.1158/1078-0432.CCR-06-2765 17545524
28. Age-specific differences in oncogenic pathway deregulation seen in human breast tumors. CK Anders CR Acharya DS Hsu G Broadwater K Garman JA Foekens Y Zhang Y Wang K Marcom JR Marks S Mukherjee JR Nevins KL Blackwell A Potti, PLoS ONE 2008 3 e1373 18167534 10.1371/journal.pone.0001373
29. A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer. M Chanrion V Negre H Fontaine N Salvetat F Bibeau G Mac Grogan L Mauriac D Katsaros F Molina C Theillet JM Darbon, Clin Cancer Res 2008 14 1744 52 10.1158/1078-0432.CCR-07-1833 18347175
30. Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. A Murat E Migliavacca T Gorlia WL Lambiv T Shay MF Hamou N de Tribolet L Regli W Wick MC Kouwenhoven JA Hainfellner FL Heppner PY Dietrich Y Zimmer JG Cairncross RC Janzer E Domany M Delorenzi R Stupp ME Hegi, J Clin Oncol 2008 26 3015 24 10.1200/JCO.2007.15.7164 18565887
31. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. HS Phillips S Kharbanda R Chen WF Forrest RH Soriano TD Wu A Misra JM Nigro H Colman L Soroceanu PM Williams Z Modrusan BG Feuerstein K Aldape, Cancer Cell 2006 9 157 73 10.1016/j.ccr.2006.02.019 16530701
32. Gene expression profiles identify epithelial-to-mesenchymal transition and activation of nuclear factor-kappaB signaling as characteristics of a high-risk head and neck squamous cell carcinoma. CH Chung JS Parker K Ely J Carter Y Yi BA Murphy KK Ang AK El-Naggar AM Zanation AJ Cmelak S Levy RJ Slebos WG Yarbrough, Cancer Res 2006 66 8210 8 10.1158/0008-5472.CAN-06-1213 16912200
33. Gene-expression profiles predict survival of patients with lung adenocarcinoma. DG Beer SL Kardia CC Huang TJ Giordano AM Levin DE Misek L Lin G Chen TG Gharib DG Thomas ML Lizyness R Kuick S Hayasaka JM Taylor MD Iannettoni MB Orringer S Hanash, Nat Med 2002 8 816 24 12118244
34. Gene expression-based, individualized outcome prediction for surgically treated lung cancer patients. S Tomida K Koshikawa Y Yatabe T Harano N Ogura T Mitsudomi M Some K Yanagisawa T Takahashi H Osada T Takahashi, Oncogene 2004 23 5360 70 10.1038/sj.onc.1207697 15064725
35. Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. M Raponi Y Zhang J Yu G Chen G Lee JM Taylor J Macdonald D Thomas C Moskaluk Y Wang DG Beer, Cancer Res 2006 66 7466 72 10.1158/0008-5472.CAN-06-1191 16885343
36. Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. DG Altman B Lausen W Sauerbrei M Schumacher, J Natl Cancer Inst 1994 86 829 35 10.1093/jnci/86.11.829 8182763
37. Categorizing a prognostic variable: review of methods, code for easy implementation and applications to decision-making about cancer treatments. M Mazumdar JR Glassman, Stat Med 2000 19 113 32 10.1002/(SICI)1097-0258(20000115) 19:1<113::AID-SIM245<3.0.CO;2-O 10623917
38. On the problem of using 'optimal' cutpoints in the assessment of quantitative prognostic factors. N Holländer M Schumacher, Onkologie 2001 24 194 9 10.1159/000050315 11441304
39. Maximally selected chi square statistics. R Miller D Siegmund, Biometrics 1982 38 1011 16 10.2307/2529881
40. Ki67 protein: the immaculate deception? DC Brown KC Gatter, Histopathology 2002 40 2 11 10.1046/j.1365-2559.2002.01343.x 11903593
41. The Six1 homeoprotein stimulates tumorigenesis by reactivation of cyclin A1. RD Coletta K Christensen KJ Reichenberger J Lamb D Micomonaco L Huang DM Wolf C Muller-Tidow TR Golub K Kawakami HL Ford, Proc Natl Acad Sci USA 2004 101 6478 83 15123840 10.1073/pnas.0401139101
42. Six1 overexpression in mammary cells induces genomic instability and is sufficient for malignant transformation. RD Coletta KL Christensen DS Micalizzi P Jedlicka M Varella-Garcia HL Ford, Cancer Res 2008 68 2204 13 10.1158/0008-5472.CAN-07-3141 18381426
43. Six1 overexpression in ovarian carcinoma causes resistance to TRAIL-mediated apoptosis and is associated with poor survival. K Behbakht L Qamar CS Aldridge RD Coletta SA Davidson A Thorburn HL Ford, Cancer Res 2007 67 3036 42 10.1158/0008-5472.CAN-06-3755 17409410
44. Clinicopathological significance of homeoprotein Six1 in hepatocellular carcinoma. KT Ng K Man CK Sun TK Lee RT Poon CM Lo ST Fan, Br J Cancer 2006 95 1050 5 10.1038/sj.bjc.6603399 17008870
45. Abrogation of the G2 cell cycle checkpoint associated with overexpression of HSIX1: a possible mechanism of breast carcinogenesis. HL Ford EN Kabingu EA Bump GL Mutter AB Pardee, Proc Natl Acad Sci USA 1998 95 12608 13 9770533 10.1073/pnas.95.21.12608
46. Gene amplification is a mechanism of Six1 overexpression in breast cancer. KJ Reichenberger RD Coletta AP Schulte M Varella-Garcia HL Ford, Cancer Res 2005 65 2668 75 10.1158/0008-5472.CAN-04-4286 15805264
47. A novel candidate oncogene, MCT-1, is involved in cell cycle progression. M Prosniak J Dierov K Okami B Tilton B Jameson BE Sawaya RB Gartenhaus, Cancer Res 1998 58 4233 7 9766643
48. MCT-1 oncogene contributes to increased in vivo tumorigenicity of MCF7 cells by promotion of angiogenesis and inhibition of apoptosis. AS Levenson KE Thurn LA Simons D Veliceasa J Jarrett C Osipo VC Jordan OV Volpert RL Satcher Jr RB Gartenhaus, Cancer Res 2005 65 10651 6 10.1158/0008-5472.CAN-05-0845 16322206
49. Gene expression profiling predicts clinical outcome of breast cancer. LJ van't Veer H Dai MJ van de Vijver YD He AA Hart M Mao HL Peterse K van der Kooy MJ Marton AT Witteveen GJ Schreiber RM Kerkhoven C Roberts PS Linsley R Bernards SH Friend, Nature 2002 415 530 6 10.1038/415530a 11823860
50. Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis. R Mehra S Varambally L Ding R Shen MS Sabel D Ghosh AM Chinnaiyan CG Kleer, Cancer Res 2005 65 11259 64 10.1158/0008-5472.CAN- 05-2495 16357129
51. Alterations of the HBP1 transcriptional repressor are associated with invasive breast cancer. KE Paulson K Rieger-Christ MA McDevitt C Kuperwasser J Kim VE Unanue X Zhang M Hu R Ruthazer SP Berasi CY Huang D Giri S Kaufman JM Dugan J Blum G Netto DE Wazer IC Summerhayes AS Yee, Cancer Res 2007 67 6136 45 10.1158/0008-5472.CAN-07-0567 17616670
52. CUL7 is a novel antiapoptotic oncogene. SS Kim M Shago L Kaustov PC Boutros JW Clendening Y Sheng GA Trentin D Barsyte-Lovejoy DY Mao R Kay I Jurisica CH Arrowsmith LZ Penn, Cancer Res 2007 67 9616 22 10.1158/0008-5472. CAN-07-0644 17942889
53. A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients. H Dai L van't Veer J Lamb YD He M Mao BM Fine R Bernards M van de Vijver P Deutsch A Sachs R Stoughton S Friend, Cancer Res 2005 65 4059 66 10.1158/0008-5472.CAN-04-3953 15899795
54. Influence of hospital procedure volume on outcomes following surgery for colon cancer. D Schrag LD Cramer PB Bach AM Cohen JL Warren CB Begg, JAMA 2000 284 3028 35 10.1001/jama.284.23.3028 11122590
55. Multimodality therapy for pancreatic cancer in the U.S. KY Bilimoria DJ Bentrem CY Ko JS Tomlinson AK Stewart DP Winchester MS Talamonti, Cancer 2007 110 1227 34 10.1002/cncr.22916 17654662
56. Specialized care and survival of ovarian cancer patients in The Netherlands: nationwide cohort study. F Vernooij AP Heintz PO Witteveen M van der Heiden-van der Loo JW Coebergh Y van der Graaf, J Natl Cancer Inst 2008 100 399 406 10.1093/jnci/djn033 18334710
57. Advances in isolation and characterization of homogeneous cell populations using laser microdissection. S Mizuarai K Takahashi T Kobayashi H Kotani, Histol Histopathol 2005 20 139 46 15578433
58. Gene-expression signatures in oncology diagnostics. A Mazumder Y Wang, Pharmacogenomics 2006 7 1167 73 10.2217/14622416.7.8.1167 17184204
59. Summaries of Affymetrix GeneChip probe level data. RA Irizarry BM Bolstad F Collin LM Cope B Hobbs TP Speed, Nucleic Acids Res 2003 31 e15 12582260 10.1093/nar/gng015
60. Reliability and reproducibility issues in DNA microarray measurements. S Draghici P Khatri AC Eklund Z Szallasi, Trends Genet 2006 22 101 9 16380191 10.1016/j.tig.2005.12.005
61. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. RL Camp M Dolled-Filhart DL Rimm, Clin Cancer Res 2004 10 7252 9 10.1158/1078-0432.CCR-04-0713 15534099